We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




A Host Protein Interferes with the Immune System's Ability to Deal with DNA Viruses

By LabMedica International staff writers
Posted on 27 Apr 2016
Print article
Image: A confocal fluorescence microscopy image of NLRX1 (green) in a HeLa cell (blue, nuclear stain) (Photo courtesy of Dr. Haitao Guo, University of North Carolina).
Image: A confocal fluorescence microscopy image of NLRX1 (green) in a HeLa cell (blue, nuclear stain) (Photo courtesy of Dr. Haitao Guo, University of North Carolina).
A team of molecular immunologists has identified a human protein that interferes with the ability of the immune system to ward off infections caused by viruses such as HIV.

Investigators at the Sanford Burnham Prebys Medical Discovery Institute (La Jolla, CA, USA) and their colleagues at the University of North Carolina (Chapel Hill, USA) focused their attention on NLRX1 (nucleotide-binding oligomerization domain, leucine rich repeat containing X1), an NLR protein that earlier had been identified in an unbiased siRNA (short interfering RNA) screen as being required for HIV infection.

The investigators reported in the April 13, 2016, issue of the journal Cell Host & Microbe that depletion of NLRX1 impaired the ability of HIV to infect cells by blocking nuclear import of HIV-1 DNA into human monocytic cells. Although HIV is a single-stranded RNA virus, reverse transcriptase enzymes in immune cells rapidly convert the viral genetic package into DNA, increasing the level of DNA found in the cytosol.

When NLRX1 was present, it was observed to reduce production of type-I interferon (IFN-I) and immune system stimulating cytokines in response to HIV-1 reverse-transcribed DNA. In addition, NLRX1 sequestered the DNA-sensing adaptor STING (stimulator of interferon genes) and prevented it from interacting with the enzyme TANK-binding kinase 1 (TBK1), which is required for IFN-1 induction in response to DNA.

Mice that had been genetically engineered to lack the gene for producing NLRX1 exhibited enhanced innate immunity and reduced viral load when infected with DNA viruses. Thus, NLRX1 acted as a negative regulator of the host innate immune response to HIV-1 and DNA viruses.

“Our study provides critical insight on a paramount issue in HIV research: Why is the body unable to mount an efficient immune response to HIV to prevent transmission?” said contributing author Dr. Sumit Chanda, professor of immunology at the Sanford Burnham Prebys Medical Discovery Institute. “This research shows that the host protein NLRX1 is responsible - it is required for HIV infection and works by repressing the innate immune response. Importantly, we were able to show that deficiencies in NLRX1 reduce HIV replication, suggesting that the development of small molecules to modulate the innate immune response may inhibit viral transmission and promote immunity to infection. We anticipate expanding our research to identify NLRX1 inhibitors.”

“Our discovery that NLRX1 reduces the immune response to HIV is similar to the discovery of host immune checkpoints, such as PD-L1 and CTLA-1, that control the immune response to cancer,” said senior author Dr. Jenny Ting, professor of microbiology and immunology at the University of North Carolina. “Checkpoint inhibitors have made a huge impact on cancer treatment, and significant investment by the biotech/pharmaceutical sector is being made to identify STING inhibitors as the next generation of immune-oncology therapeutics. This study, showing that NLRX1 is a checkpoint of STING, sheds more light on the topic and will help advance those efforts.”

Related Links:
Sanford Burnham Prebys Medical Discovery Institute
University of North Carolina
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.